Colistin

Therapeutic

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Structural features

SMILES

CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O

Sequence

XXT-XX(1)XlLXXT(1)

Molar mass

1155.455 g/mol

Constitutional members:

11

Natural amino acids

3

D-Amino acids

1

N-terminus

5-methyl-heptanoyl

C-terminus

cycle

Cyclic

yes

Members/cycle

7

Bond to form cycle

head-to-side chain (Thr-Dab)

Lipidation

yes

Glycosylation

no

Route of administration

AURICULAR

Terminal half-life

5 hours

Protein binding

-

Absorption and Bioavailability

Peak serum levels after intravenous (i.v.) administration are achieved within 10 min. They appeared higher but declined more rapidly than those achieved after i.m. administration

References